GLP-1 Peptide Atlas, by Delfa

UnknownPhase EARLY_1

[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients

A Pilot Prospective Comparison of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients

Lead sponsor

Peking Union Medical College Hospital

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Oncology

Key I/E criterion

—

Primary endpoint

•Metabolic parameters

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05034783

Org study IDPUMCH-NM-EX4

Timeline

Milestones

Study first posted2021-09-05actual

Study start2021-10-01actual

Primary completion2022-10-13actual

Last update posted2022-10-14actual

Study completion2023-06-01estimated

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Oncology

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•confirmed treated or untreated insulinoma patients;

•[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT within two consecutive days;

•signed written consent.

Exclusion criteria

•pregnancy;

•breastfeeding;

•known allergy against exendin-4;

•any medical condition that in the opinion of the investigator may significantly interfere with study compliance

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Diagnostic value

Time frame:through study completion, an average of 1 year

descriptive

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Metabolic parameters

Time frame:through study completion, an average of 1 year

descriptive

Other/protocol endpoint/low confidence

GLP-1R expression and SUV

Time frame:through study completion, an average of 1 year

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.
Clinical nuclear medicine2025 Jan 1PMID39499011doi:10.1097/RLU.0000000000005533via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.